PLUS THERAPEUTICS CEO Awarded 7.66M Equity Instruments with Multi‑Year Vesting
Rhea-AI Filing Summary
PLUS THERAPEUTICS, Inc. (PSTV) reported an equity award to Marc H. Hedrick, its Chief Executive Officer and a director. On 08/13/2025 he was granted stock options to purchase 5,748,506 shares with an exercise price of $0.5744 and an expiration date of 08/12/2035, and 1,916,168 restricted stock units that convert one-for-one into common stock upon vesting. The option grant vests monthly over four years in equal 1/48th installments. The RSUs vest over three years with one-third vesting on the first anniversary and the remaining two-thirds vesting monthly over the following two years.
Positive
- 5,748,506 stock options were granted to Marc H. Hedrick with clear terms including exercise price $0.5744 and expiration 08/12/2035
- 1,916,168 RSUs were awarded that convert one-for-one into common stock upon vesting
- Vesting schedules disclosed: options vest monthly over four years; RSUs vest 1/3 after one year then monthly over two years
Negative
- None.
Insights
TL;DR Significant management equity grants were awarded, creating potential future dilution and aligning compensation with long-term equity performance.
The filing documents a large option grant of 5,748,506 shares at an exercise price of $0.5744 expiring in 2035, plus 1,916,168 RSUs. The options vest monthly over four years and the RSUs vest 1/3 after one year then monthly over two years. For valuation and dilution analysis, model the potential share count increase of 7,664,674 total shares if all instruments vest and convert. These awards are time‑based with multi‑year vesting, indicating retention and long‑term alignment objectives embedded in compensation structure.
TL;DR CEO and director received time‑based equity awards with multi‑year vesting; disclosure is clear on vesting schedules and instrument terms.
The Form 4 clearly discloses the grant dates, quantities, exercise price, expiration, and vesting schedules for both options and RSUs. The report is filed individually for Marc H. Hedrick and is signed by an attorney‑in‑fact. From a governance and disclosure perspective, the filing meets Form 4 requirements by specifying grant mechanics and ownership form as direct. Further assessment would require company total share count and prior awards to judge materiality relative to shareholder interests.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 5,748,506 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 1,916,168 | $0.00 | -- |
Footnotes (1)
- The option vest over four years in equal 1/48th increments on each monthly anniversary of the issuance. The Restricted Stock Units (RSUs) awarded on August 13, 2025 vest over three years, with 1/3rd vesting on the first anniversary of the Grant Date and the remaining 2/3rds vesting in equal monthly installments over the following two years. The RUSs convert into shares of Common Stock upon vesting on a one for one basis.